Prof. Shiliang Li
Purple River Young Scholar, Doctoral Supervisor
Room 301, South of Physics Building
slli@hsc.ecnu.edu.cn
Education
l 2016.06 Ph.D. Computational Chemistry, School of Pharmacy, East China University of Science&Technology, (Supervisor: Prof. Honglin Li)
l 2011.06 B.E. Pharmaceutical Engineering, School of Pharmacy, East China University of Science&Technology
Professional Experience
l 2023-now Research fellow, Innovation Center for AI and Drug Discovery, East China Normal University
l 2019.08-2022.12 Associate professor, School of Pharmacy, East China University of Science and Technology
l 2018.11-2019.07 Distinguished associate research fellow, School of Pharmacy, East China University of Science and Technology
l 2016.07-2018.10 Postdoctor, School of Pharmacy, East China University of Science and Technology
Research Interests
l Development of AIDD methods and their application
l Construction of target-disease knowledge graph
l Discovery of novel drugs for metabolic diseases
Publication
1. Ziyan Feng, Zihao Shen, Honglin Li, Shiliang Li*. e-TSN: an interactive visual exploration platform for target-disease knowledge mapping from literature. Briefings Bioinf., 2022. 23(6) : bbac465.
2. Rui Xiong#, Leike Zhang#, Shiliang Li#, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, Honglin Li*, Ke Xu*. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & Cell, 2020. 11: 723–739. （封面文章）
3. Fanxun Zeng#, Shiliang Li#, Guantian Yang#, Yating Luo#, Tiantian Qi, Yingfan Liang, Tingyuan Yang, Letian Zhang, Rui Wang*, Lili Zhu*, Honglin Li*, Xiaoyong Xu*. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. Acta Pharm. Sin. B. 2021. 11(3): 795-809.（封面文章）
4. Shiliang Li#, Chun Qin#, Shichao Cu#, Hongling Xu, Fangshu Wu, Jiawei Wang, Mingbo Su, Xiaoyu Fang, Dan Li, Qian Jiao, Ming Zhang, Chunmei Xia, Lili Zhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao*, Jing-Ya Li*, Honglin Li*. Discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes. J. Med. Chem. 2019. 62(5): 2348-2361.（封面文章）
5. Shiliang Li#, Hongling Xu#, Shichao Cui#, Fangshu Wu#, Youli Zhang, Mingbo Su, Yinghui Gong, Shaobing Qiu, Qian Jiao, Chun Qin, Jiwei Shan, Ming Zhang, Jiawei Wang, Qiao Yin, Minghao Xu, Xiaofeng Liu, Rui Wang, Lili Zhu, Jia Li, Yufang Xu, Hualiang Jiang, Zhenjiang Zhao*, Jingya Li*, Honglin Li*. Discovery and rational design of natural product-derived 2-phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine analogs as novel and potent DPP-4 inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 2016, 59 (14), 6772-6790.
6. Yuan Yuan#, Junpeng Xu#, Lei Jiang#, Kangjie Yu#, Yuanyuan Ge, Mingyang Li, Huan He, Qiqi Niu, Xiayu Shi, Linni Fan, Zhuo Chen, Zhenjiang Zhao, Shiliang Li*, Yufang Xu*, Zhe Wang*, Honglin Li*. Discovery, optimization, and structure-activity relationship study of novel and potent RSK4 inhibitors as promising agents for the treatment of esophageal squamous cell carcinoma. J. Med. Chem. 2021. 64(18): 13572-13587.
7. Guixiang Yang, Songlan Ge, Yanwu, Jin Huang, Shiliang Li*, Rui Wang*, Lei Ma*. Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents. Eur. J. Med. Chem. 2018, 156, 206-215.
8. Shiliang Li, Chaoqian Cai, Jiayu Gong, Xiaofeng Liu, Honglin Li*. A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing. Proteins. 2021, 89(11): 1541-1556. （封面文章）
9. Disha Wang, Zihao Shen, Lei Jiang, Wenjun Liu, Jie Wang, Shiliang Li*, Honglin Li*. Deep learning based drug metabolites prediction. Front. Pharmacol. 2020. 10: 1586.
10. Shiliang li#, Yi Zhou#, Weiqiang Lu#, Ye Zhong, Jin Huang*, zhenjiang zhao, Xiaofeng Liu*, Yufang Xu, Honglin Li. Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-based Virtual Screening with the Inhibitor-constrained Refined Homology Model. J. Chem. Inf. Model. 2011. 51(11) : 2939-2947.